Objective-Class III phosphoinositide 3-kinase, also known as VPS34 (vacuolar protein sorting 34), is a highly conserved enzyme regulating important cellular functions such as NADPH oxidase (NOX) assembly, membrane trafficking, and autophagy. Although VPS34 is expressed in platelets, its involvement in platelet activation remains unclear. Herein, we investigated the role of VPS34 in platelet activation and thrombus formation using VPS34 knockout mice. Approach and Results-Platelet-specific VPS34-deficient mice were generated and characterized. VPS34 deficiency in platelets did not influence tail bleeding time. In a ferric chloride-induced mesenteric arteriolar thrombosis model, VPS34 −/− mice exhibited a prolonged vessel occlusion time compared with wild-type mice (42.05±4.09 versus 18.30±2.47 minutes). In an in vitro microfluidic whole-blood perfusion assay, thrombus formation on collagen under arterial shear was significantly reduced for VPS34 −/− platelets. VPS34 −/− platelets displayed an impaired aggregation and dense granule secretion in response to low doses of collagen or thrombin. VPS34 deficiency delayed clot retraction but did not influence platelet spreading on fibrinogen. We also demonstrated that VPS34 deficiency altered the basal level of autophagy in resting platelets and hampered NOX assembly and mTOR (mammalian target of rapamycin) signaling during platelet activation. Importantly, we identified the NOX-dependent reactive oxygen species generation as the major downstream effector of VPS34, which in turn can mediate platelet activation. In addition, by using a specific inhibitor 3-methyladenine, VPS34 was found to operate through a similar NOX-dependent mechanism to promote human platelet activation. Conclusions-Platelet VPS34 is critical for thrombosis but dispensable for hemostasis. VPS34 regulates platelet activation by influencing NOX assembly. Visual Overview-An online visual overview is available for this article.
C irculating platelets form hemostatic plugs to prevent blood loss on vascular injury, although excessive activation of platelets may cause pathological thrombosis and lead to lifethreatening diseases such as myocardial infarction and stroke. On activation, platelets undergo cytoskeletal reorganization, calcium mobilization, granule content release, adhesion, and aggregation through integrin αIIbβ3 activation and eventually form thrombi. 1 A wide array of these platelet activation events are subject to the regulation of phosphoinositide 3-kinases (PI3Ks), [2] [3] [4] which are responsible for producing the second messengers D3-phosphorylated phosphoinositides. 5 Elucidating the functions of PI3Ks in platelets may provide essential information for the regulation mechanisms of thrombosis and hemostasis.
Platelets express various PI3K isoforms. The class I PI3Ks, especially PI3Kβ and PI3Kγ, critically contributing to platelet signal transduction and activation, have well-characterized roles in arterial thrombosis. 2, 3 PI3KC2α, which belongs to the class II PI3Ks, is essential for maintaining the normal internal plasma membrane structure (the open canalicular system) of platelets. 6 Genetic inactivation of PI3KC2α leads to a reduced shear-dependent platelet adhesion and thrombi stability. 6, 7 We have previously reported that human platelets harbor the single isoform of the class III PI3K, also known as PI3KC3 or VPS34 (vacuolar protein sorting 34). Pharmacological inhibition study suggests that VPS34 may be another important regulator of platelet function in the PI3K family. 8 However, the detailed mechanisms of VPS34 in platelets remain largely unknown.
VPS34 uses phosphatidylinositol to generate phosphatidylinositol 3-phosphate (PI(3)P), which coordinates the localization and function of multiple effector proteins to mediate and thereby VPS34 mediates the assembly of NADPH oxidase (NOX), which subsequently promotes reactive oxygen species (ROS) generation. 12, 13 Another well-known function of VPS34 is to direct autophagic process, which is critically dependent on the interactions between PI(3)P and its effector proteins such as DCFP1 (doubleFYVE domain-containing protein 1) or WIPI (WD-repeat protein interacting with phosphoinositides) family proteins. 14, 15 Interestingly, both ROS generation [16] [17] [18] and autophagy 19 have been reported to be essential in proper platelet activation and thrombus formation. Besides, VPS34 was shown to regulate the mTOR (mammalian target of rapamycin) Complex1/ S6K1 signaling pathway, 20, 21 which in itself is important for platelet engagement on fibrinogen and platelet clot retraction. 22, 23 Nevertheless, it is currently unknown whether and how platelets may use these VPS34-mediated pathways to support their activation and participate in thrombosis and hemostasis.
In this study, by using megakaryocyte/platelet-specific VPS34-deficient mice, we confirm that VPS34 is an important positive regulator of platelet activation. We have further demonstrated that NOX-mediated ROS generation is the dominant executor of VPS34 function in platelets. In vivo, platelets VPS34 seems to only influence occlusive thrombosis but not the bleeding time.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results
Megakaryocyte/Platelet-Specific VPS34-Deficient Mice Show Normal Thrombopoiesis and Platelet Morphology PF4-Cre + VPS34 f/f mice were genotyped by polymerase chain reaction ( Figure 1A) , and the ablation of VPS34 protein in platelets was confirmed by Western blot ( Figure 1B ). Platelet-specific VPS34 deficiency mice were viable and fertile and did not exhibit any evident bleeding tendency or thrombotic events over their lifespan. Platelet VPS34 −/− mice and wild-type (WT) littermates did not differ significantly in platelet counts, red blood cell counts, white blood cell counts, hematocrits, and hemoglobin concentrations (Table) . Similar to what have been reported in other cell types, [24] [25] [26] VPS34 deficiency in platelet is associated with a largely decreased expression of VPS15 and Beclin-1, two of its main binding partners ( Figure 1B ). However, the expression level of the major regulatory subunit of the class IA PI3K, p85, is intact ( Figure 1B ). In addition, there were no significant differences in the surface expression of the platelet glycoproteins (glycoprotein VI [GPVI]), CD41 (αIIb subunit), and CD42b (GPIbα subunit; Figure 1C ). Electron microscopic analysis of VPS34-deficient platelets did not reveal any ultrastructural abnormalities, including the morphology of open canalicular system, and the numbers of α-granules and dense granules ( Figure 1D ).
VPS34 −/− Mice Display Impaired Thrombus Formation In Vivo and In Vitro
The role of VPS34 in hemostasis was investigated in a tail bleeding assay. In the FeCl 3 induced in mesentery artery injury model, VPS34-deficient mice failed to form stable thrombi at the same time when the vessels of WT mice were occluded (42.05±4.09 versus 18.30±2.47 minutes; Figure 2A ). The bleeding times were comparable for WT mice and VPS34 −/− mice (236.1±42.47 versus 312.6±49.11 s; Figure 2B ). We next assessed the role of platelet VPS34 in thrombus formation under arterial flow conditions using a microfluidic whole-blood perfusion assay. Throughout the perfusion period (5 minutes), the thrombi formed by VPS34 −/− platelets were significantly smaller than those formed by WT platelets ( Figure 2C ). These results suggest that VPS34 deficiency in platelets does not influence hemostasis; however, it prevents stable arterial thrombosis. Similar to VPS34-deficient mice platelets, human platelets pretreated with VPS34 inhibitor (3-methyladenine [3-ma] ) failed to adhere to collagen matrix properly ( Figure I in the online-only Data Supplement).
VPS34
−/− Platelets Show Impaired Aggregation, Granule Secretion, and a Delayed Clot Retraction
To further characterize the role of VPS34 in platelet activation, platelet aggregation in response to common stimuli was analyzed. Loss of VPS34 significantly inhibited platelets aggregation and dense granule secretion induced by low concentrations of collagen (0.5 μg/mL) and thrombin (0.025 U/mL), but not by higher concentrations of these agonists (1 μg/mL collagen and 0.05 U/mL thrombin; Figure 3A ). VPS34-deficient platelets also showed a defective aggregation in response to low concentration (5 μmol/L) but not higher concentration of ADP (20 μmol/L; Figure 3A) . On thrombin or collagen stimulation, treating cells with apyrase equally reduced aggregation of VPS34 −/− and WT platelets, but it did not abolish the aggregation difference between VPS34 −/− and WT platelets ( Figure  IIA in the online-only Data Supplement), indicating that apart from a reduced ADP secretion and a hampered responsiveness toward ADP, VPS34 deficiency disrupted thrombin-or collagen-stimulated signaling per se. Moreover, thrombin-or collagen-stimulated phosphorylation of Syk (spleen tyrosine kinase) and PLCγ2, but not that of MAPKs (mitogen-activated protein kinases; ERK1/2 [extracellular stimuli-responsive kinase 1/2] and p38), was significantly decreased in VPS34 −/− platelets ( Figure 3B ). When single platelets are measured by flow cytometry, VPS34 deficiency impairs activation of mouse αIIbβ3 and α-granule secretion (CD62P surface expression) induced by thrombin and collagen ( Figure 3C ). In washed human platelets, 3-ma dose dependently inhibited platelet aggregation and ATP release ( Figure IIB in the online-only Data Supplement). Human platelets pretreated with 3-ma also showed significantly decreased CD62P surface expression and fibrinogen binding when exposed to GPVI and PAR (protease-activated receptor) stimulation ( Figure IIC in the online-only Data Supplement).
We next assessed platelet spreading on immobilized fibrinogen and clot retraction, 2 processes dependent on early and late integrin αIIbβ3-mediated outside-in signaling, respectively. [27] [28] [29] VPS34-deficient platelets displayed significantly delayed clot retraction ( Figure 3D ). However, platelet spreading on immobilized fibrinogen was comparable between WT and VPS34 −/− mice ( Figure 3D ). Moreover, VPS34 deficiency did not influence integrin αIIbβ3 mediated early outside-in signaling, as shown by a similar tyrosine phosphorylation of β3 cytoplasmic tail and Src family kinase in WT and VPS34 −/− platelets while spreading on immobilized fibrinogen ( Figure  IIIA in the online-only Data Supplement). These data suggest that VPS34 deficiency do not affect early stage outside-in signaling, but it plays an important role in the platelet retractile signaling pathway leading to clot retraction. In isolated human platelets, 3-ma significantly prevented clot retraction in human platelet-rich plasma ( Figure Collectively, these results indicate that VPS34 is positively involved in inside-out signaling and conformational change of αIIbβ3 in response to GPVI and PAR activation and regulate clot retraction. −/− platelets had comparable levels of PI(3)P ( Figure 4A ). Thrombin or convulxin stimulation caused an increase of PI(3)P in both WT and VPS34 −/− platelets; however, the increment was significantly lower in VPS34 −/− platelets ( Figure 4A ). Notably, reduction of PI(3)P is associated with a minimized translocation of p40phox and p47phox to the plasma membrane and a reduced phoxp40 phosphorylation (threonine 154; Figure 4B and 4C), processes necessary for the assembly and proper function of NADPH oxidase (NOX).
13,30,31 Concomitantly, convulxin-or thrombin-induced ROS generation was significantly reduced in VPS34-deficient platelets ( Figure 4D ). VPS34 deficiency-caused ROS reduction was similar to WT platelet treated with NOX inhibitors diphenyleneiodonium (DPI), and DPI showed a minimum further reduction of ROS generation on VPS34 −/− platelets ( Figure 4D ). Consistently, DPI markedly inhibited platelet aggregation in WT platelets but mildly influenced VPS34 −/− platelets, and defective VPS34 −/− platelets aggregation can be overcome by supplemented H 2 O 2 ( Figure 4E ). DPI pretreated mice platelets also showed a significantly delayed clot retraction ( Figure IVA in the online-only Data Supplement). In human platelets, 3-ma decreased phosphorylation of p40phox, plasma translocation of p40phox and p47phox, PI(3)P production, and 
VPS34 Deficiency Impairs mTOR Signaling
VPS34 plays an essential role in the regulation of the mTOR signaling pathway. 20 ,21 Therefore, we tested whether VPS34 uses mTOR pathway to participate in platelet activation. Phosphorylation of S6K1 Thr389 and Akt Ser473 was used as the indicators for the activation of mTORC1 and mTORC2 pathways in platelets, respectively. 32, 33 Compared with WT platelets, VPS34 −/− platelets showed a largely decreased phosphorylation of S6K1 Thr389 after thrombin or collagen stimulation ( Figure 5A ). VPS34 −/− platelets also showed a decreased phosphorylation of Akt Ser473, whereas the phosphorylation of AKT Thr308, a process known to be mediated by PDK1 in platelets, 32 was not affected by VPS34 deficiency ( Figure 5A ). These data suggest that VPS34 deficiency impairs mTOR signaling in platelets.
To evaluate whether mTOR signaling downstream of VPS34 contributes to platelet function, platelets were incubated with PP242 (inhibitor of both mTORC1 and mTORC2) or rapamycin (inhibitor of mTORC1) and stimulated with thrombin and collagen. Neither PP242 (100 nmol/L) nor rapamycin (200 nmol/L) had significant effects on WT and VPS34 −/− platelet aggregation ( Figure 5B ) or clot retraction ( Figure VA in the online-only Data Supplement). Although increased dosage of PP242 (1000 nmol/L) or rapamycin (500 nmol/L) did inhibit platelet aggregation, they did not alter the aggregation difference between WT and VPS34 −/− platelets ( Figure VB in the online-only Data Supplement). And inhibition of mTOR signaling did not impair ROS production during platelets activation ( Figure 5C ). Moreover, NOX assembly (the translocation of p40 and p47 to the plasma membrane) was not affected by PP242 and rapamycin pretreatment ( Figure 5D ).
Because Akt phosphorylation is decreased in VPS34 −/− platelets and Akt has been reported to promote platelet activation via NOS (nitric oxide synthase)-cGMP (cyclic guanosine monophosphate) 34 and GSK3β (glycogen synthase kinase 3β), 35 we have further explored whether these pathways downstream of Akt, possibly influenced by the phosphorylation of Ser473, contribute to the phenotype of VPS34 −/− platelets. /mL), and PI(3)P production was measured using PI3P mass ELISA kit (n=3,*P<0.05, Student t test). B, Western blot analysis and quantification of membrane localized p40phox (phagocyte oxidase) and p47phox. Platelets were treated with or without collagen (0.5 μg/mL) or thrombin (0.025 U/mL). The membrane fractions were extracted and resuspended in lysis buffer for immunoblotting (n=3, **P<0.01, *** P<0.001, Student t test). C, Immunoblot analysis and quantification of p40-phoxphosphorylation during WT and VPS34 −/− platelets activation. (n=5, **P<0.01, Student t test.) D, ROS generation analyzed by flow cytometry. H 2 DCFDA (2',7'-dichlorodihydrofluorescein diacetate)-loaded (50 µmol/L) mice platelets were incubated with or without diphenyleneiodonium (DPI; 80µmol/L) for 5 min and stimulated with 0.025 U/mL thrombin (thr) or 100 ng/mL convulxin (CVX) for 5 min. Samples were analyzed immediately (n=6, **P<0.01, Student t test). E, Washed mice platelets (3×10 8 /mL) were incubated with DPI for 5 min or supplemented with H 2 O 2 , then stimulated with collagen (0.5 μg/mL) or thrombin (0.025 U/mL). Aggregation was assessed in an aggregometer under stirring at 1200 rpm (n=3, **P<0.01, Student t test). VPS indicates vacuolar protein sorting.
First, we measured GSK3β phosphorylation and found that it was not affected by VPS34 deficiency ( Figure VIA −/− platelets treated with mTOR inhibitors. H 2 DCFDA (2',7'-dichlorodihydrofluorescein diacetate)-loaded (50 µmol/L) mice platelets were incubated with or without PP242 (100 nmol/L) or rapamycin (200 nmol/L) for 5 min, respectively, and stimulated with 0.025 U/mL thrombin (thr) or 100 ng/mL convulxin (CVX) for 5 min. Samples were subject to flow cytometric analysis immediately (n=3, **P<0.01, Student t test). D, Western blot analysis and quantification of membrane localized p40phox (phagocyte oxidase) and p47phox after mice platelets treated with mTOR inhibitors. Washed mice platelets were incubated with PP242 (100 nmol/L) or rapamycin (200 nmol/L) and stimulated with collagen (0.5 μg/mL) or thrombin (0.025 U/mL). The membrane fractions were extracted and resuspended in lysis buffer for immunoblotting (n=3, *P<0.05, **P<0.01, Student t test). NS indicates no significance; and VPS, vacuolar protein sorting.
Taken together, these results suggest that mTOR signaling is impaired during VPS34 −/− platelets aggregation; however, this pathway may not directly contribute to mice platelet activation.
Impaired VPS34 −/− Platelet Activation May Not be Autophagy Dependent
Previous studies suggested that autophagy may influence platelet activation. 8, 19 We therefore evaluated whether functional defects of VPS34 −/− platelets depend on autophagic induction. During autophagy, soluble microtubule-associated protein light chain 3 (LC3)-I is converted to lipid-bound LC3-II, which is then conjugated to phosphatidylethanolamine to be presented on isolated membranes. The amount of LC3-II is tightly correlated with the number of autophagosomes, thus serving as a good indicator of autophagy. 36 Thus, LC3-II levels measured by Western blot and LC3-II-positive puncta formation visualized by fluorescent microscopy were used to monitor autophagy process in platelets. As shown in Figure 6A , LC3-II level in unstimulated VPS34 −/− platelets increased significantly, indicating an altered basal autophagic flux. On thrombin or collagen stimulation, WT and VPS34 −/− platelets exhibited a similar extent of reduction of LC3-II (eg, 0.5 μg/mL collagen reduced ≈24% of LC3-II in WT platelets and reduced ≈23% in VPS34 −/− platelets; 0.025 U/mL thrombin reduced ≈31% of LC3-II in WT platelets and reduced ≈25% in VPS34 −/− platelets; Figure 6A ). Possible involvement of VPS34-dependent autophagy in platelet activation was further investigated in the presence of lysosome inhibitor NH 4 Cl, which neutralizes lysosomal pH to suppress autophagic protein degradation and increases the LC3-II level in platelets. 19 NH 4 Cl (20 mmol/L) brought up LC3-II to a comparable levels in both unstimulated WT and VPS34 −/− platelets, thrombin or collagen stimulation again caused a similar reduction of LC3-II in both WT and VPS34 −/− platelets ( Figure 6A ). When LC3 antibody-labeled platelets were examined by confocal microscopy ( Figure 6B ), resting WT platelets displayed a diffused distribution of cytosolic LC3, whereas multiple LC3-positive puncta existed in resting VPS34 −/− platelets. On autophagy induction by starvation or rapamycin treatment, WT and VPS34 −/− platelets showed similar amount of LC3-positive puncta in cytosol. The same phenotype was observed when platelets were treated with NH 4 Cl. However, thrombin stimulation did not cause significant amount of LC3-positive puncta formation in either WT or VPS34 −/− platelets. These data indicate that VPS34 may regulate basal autophagic flux in resting platelets; however, VPS34 is not critically involved in platelet activation-associated alteration of autophagic flux. Next, 20 mmol/L NH 4 Cl or 50 µmol/L CTB (N-(4-chloro-3-trifluoromethyl-phenyl)-2-ethoxy-benzamide; inhibiting autophagy by activating histone acetyltransferase p300 37, 38 ) did not significantly inhibit WT or VPS34 −/− platelets aggregation on low concentrations of collagen or thrombin stimulation ( Figure 6C and 6D) . These data indicate that inhibiting autophagy does not resemble the phenotype of VPS34 −/− platelets. Moreover, NH 4 Cl and CTB did not influence clot retraction of WT or VPS34 −/− platelets ( Figure  VII in the online-only Data Supplement). Collectively, these results suggest that the inhibition of platelet function caused by VPS34 deficiency may not be autophagy dependent.
Discussion
This study demonstrates that class III PI3K, namely VPS34, is an important regulator of platelet functions. We show that VPS34 is critically involved in platelet activation induced by both GPCR (G-protein-coupled receptors) and GPVI. VPS34 mediates multiple biological processes and signaling pathways in platelets, such as NOX assembly, mTOR pathway, and autophagy. We further identify that NOXdependent ROS generation is the dominant mechanism of VPS34 in platelet activation. Importantly, platelet VPS34 is critical for thrombosis but dispensable for hemostasis in vivo, indicating that VPS34 might serve as a promising antithrombotic target.
In consistent with the role of VPS34 as type III PI3K, platelet VPS34 deficiency leads to a reduced PI(3)P production. Specifically, our results show that VPS34 is responsible for activation-dependent PI(3)P production, but not the basic housekeeping level of PI(3)P in platelets. The latter has been reported to be mainly under the regulation of PI3KC2α 6 and possibly PI(5)P and PI(4)P. 39 Indeed, in contrast to the massive altered platelet membrane structure on PI3KC2α deletion, VPS34 deficiency does not influence platelet morphology. This indicates that PI(3)P levels in resting and activated platelets are differentially regulated, and VPS34 seems to be the main source of PI(3)P production during platelets activation. The functional importance of VPS34-mediated PI(3)P production is underscored by the findings that different types of major activating receptors, such as GPCR and GPVI-ITAM (immunoreceptor tyrosine-based activation motif), both depend on VPS34 to evoke full platelet activation. Similar dependency on VPS34 by GPCR and ITAM-containing receptors has been reported previously in myeloid cells such as neutrophils 40 and mast cells, 41 in which a direct interaction and recruitment of VPS34 by these receptors has been suggested. Although the spatial temporal dynamics of VPS34 in platelets still remains to be elucidated, our results clearly supported that VPS34-mediated PI(3)P production constitutes a central check point for platelet activation and thrombus formation.
Downstream of VPS34-mediated PI(3)P production, NADPH oxidase has been identified as the dominant executor involved in platelet aggregation in our study. NOXs are known to be responsible for the generation of superoxide anion (O 2 − ), and our results demonstrated a remarkable decrease of activation-dependent ROS generation in VPS34 −/− platelets. Moreover, DPI abolished the aggregation difference between VPS34 −/− and WT platelets. It is known that platelet express NOX1, NOX2, and NOX4, and a recent study has revealed that NOX1 and NOX2 have important impacts on platelet function. 18 As such, NOX1 is selectively important for GPCR-dependent ROS generation, whereas NOX2 is important for both GPVI-ITAM-and GPCR-induced ROS generation. 18 In the current study, several lines of evidence support that VPS34 may selectively regulate NOX2: (1) VPS34 deficiency caused a reduction of ROS generation and an impaired platelet aggregation in response to both GPCR (thrombin receptors) and GPVI-ITAM (collagen and convulxin) activation; (2) consistent with the findings in NOX2 −/− platelets, 18 thrombin-or collagen-stimulated phosphorylation of Syk and PLCγ2, but not that of MAPKs (ERK1/2 and p38), was significantly decreased in VPS34 −/− platelets; (3) the phosphorylation of p40phox Thr154 and the translocation of p40phox and p47phox to plasma membrane, specific markers for NOX2 assembly, were significantly decreased in VPS34 −/− platelets. Notably, p40phox is a unique subunit of NOX2, and thus, it bears no resemblance to any subcomponent of NOX1. Importantly, the p40phox PX domain displays a high binding specificity toward PI(3)P. 10, 11, 42 Moreover, p40phox Thr154 phosphorylation is critical in the rearrangement of the ternary complex consisting of p47phox, p67phox, and p40phox during the respiratory burst. 13, 30, 40 However, given the lack of highly selective inhibitors to different NOX isoforms or NOX isoform-specific genetic ablation models, we cannot exclude the possible involvement of the other NOXs such as NOX1 or NOX4 in VPS34-mediated platelet activation. Nevertheless, we clearly demonstrated that the main contribution of VPS34 to platelet activation is through NOX2 assembly and subsequent ROS generation.
In addition to NOX assembly and ROS generation, we also reveal that VPS34 regulates mTOR pathways in platelets. mTOR conducts signaling through the formation of 2 complexes, that is, mTORC1 and mTORC2. In platelets, mTORC1 has been reported to mediate S6K1 activation, 22, 23 whereas mTORC2 is responsible for Ser473 phosphorylation of AKT. 33 Our results demonstrated a significantly decreased phosphorylation of S6K1 Thr389 and Akt Ser473 in VPS34 −/− platelets stimulated by thrombin and collagen, which in turn indicates that VPS34 deficiency impacts both mTORC1 and mTORC2 pathways. However, using an mTOR inhibitor PP242 (100 nmol/L) and a selective mTORC1 inhibitor rapamycin (200 nmol/L), we did not observe changes of aggregation induced by collagen and thrombin stimulation in either WT or VPS34 −/− platelets. Although mTORC1 deficiency or its inhibition by rapamycin has been shown to block the platelet activation, 43 the effect was confined to the platelets from aged mice (16 months old). When the platelets were obtained from young mice (4 months old, similar to the age of mice in the current study), their activation was not influenced by mTORC1 deficiency or rapamycin. Moreover, our results are in agreement with the previous reports that the same dosage of PP242 or rapamycin did not affect platelet aggregation. 32, 33 Furthermore, in line with a previous report, 32 our current study ( Figure V in the online-only Data Supplement) found no effects on clot retraction by the mTORC1 inhibitor rapamycin. However, given that most data, including ours, were derived from mice models, we thus cannot exclude the possibility that mTOR may play roles in regulating human platelet function, as mTOR has been reported to drive human platelet spreading 22 and control clot retraction through de novo Bcl-3 (B-cell lymphoma 3) synthesis. 23 Interestingly, mTOR signaling has also been linked to important phenotypes such as platelet production 44 and age-related deep vein thrombosis. 43 Consequently, whether VPS34 regulates these mTOR-related megakaryocyte and platelet functions remains to be further investigated.
In the current study, based on the change of LC3-II levels, we found that VPS34 regulates basal level of autophagy in resting platelets, but VPS34 does not seem to be critically involved in activation-associated alteration of autophagic flux in platelets. This indicates that autophagy induction during platelet activation may be largely VPS34 independent, echoing a previous finding in mammalian sensory neurons, where functional autophagy flux still exists on VPS34 ablation. 45 Moreover, the pharmacological inhibition of the autophagic flux at different regulation points (CTB, by activating histone acetyltransferase p300, and NH 4 Cl, by inducing lysosomal pH neutralization) do not phenocopy the platelet aggregation defects caused by VPS34 deficiency, suggesting that the role of VPS34 in platelets activation may not be autophagy dependent. This conclusion is further supported by the observation that the ablation of ATG7, a pivotal regulator of autophagy, 46 does not cause severely compromised platelet function in vitro. 19 Although the current PF4-Cre system causes VPS34 deficiency in mature megakaryocytes, 47 it does not seem to influence the function of megakaryocytes, as PF4-Cre VPS34 flox/flox mice did not display any abnormalities in platelet counts, platelet morphology, or the expression of important surface proteins. It is thus likely that the observed functional change is caused by VPS34 deficiency in platelets per se. Nevertheless, we cannot rule out the possibility that VPS34 deficiency in megakaryocytes may affect the autophagic targeting and degradation of certain signaling proteins, which, on their passing on to platelets, may dampen signaling activities required for proper platelet function. Despite the lack of direct evidence in megakaryocytes and platelets, degradation of signaling proteins such as Src by selective autophagy has been previously reported. 48 Thus, the role and mechanism of autophagy in megakaryocytes and platelets, as well as their contribution to thrombosis and hemostasis, warrant further study.
To summarize, this study demonstrates a pivotal role of class III PI3K VPS34 in platelet activation induced by both GPCR and GPVI, mainly through NOX-dependent ROS generation. Human and mice platelets share a conserved VPS34-dependent mechanism in regulating their activation. Platelet VPS34 is critical for thrombosis but dispensable for hemostasis in vivo, thus suggesting that VPS34 may have the potential to become a promising target to improve antithrombotic strategy.
